TrialEuropean journal of cancer (Oxford, England : 1990)2023

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

Mark E Robson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.